Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
600800 Tian Jin Bohai Chemical
- 3.30
- +0.30+10.00%
Not Open Apr 24 15:00 CST
3.66BMarket Cap-5.80P/E (TTM)
3.30High2.97Low562.37KlotVolume3.01Open3.00Pre Close175.46MTurnover5.07%Turnover RatioLossP/E (Static)1.11BShares5.3152wk High2.08P/B3.66BFloat Cap1.8452wk Low3.30Limit Up1.11BShs Float23.40Historical High2.70Limit Down11.00%Amplitude1.01Historical Low--Dividend TTM3.12Avg Price295.54KlotAsk--Div YieldTTM100Lot Size264.48KlotBid
Tian Jin Bohai Chemical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 48.31%4.78B | 37.71%3.38B | 74.69%2.51B | 150.87%1.31B | -46.67%3.23B | -24.34%2.45B | -29.30%1.43B | -38.96%520.48M | 42.42%6.05B | 4.79%3.24B |
| Operating revenue | 48.31%4.78B | 37.71%3.38B | 74.69%2.51B | 150.87%1.31B | -46.67%3.23B | -24.34%2.45B | -29.30%1.43B | -38.96%520.48M | 42.42%6.05B | 4.79%3.24B |
| Other operating revenue | 118.97%637.86K | ---- | 45.82%456.68K | ---- | -54.64%291.3K | ---- | -30.09%313.18K | ---- | 29.31%642.23K | ---- |
| Total operating cost | 41.99%5.51B | 35.47%3.95B | 66.17%2.9B | 132.42%1.51B | -36.47%3.88B | -17.89%2.91B | -20.80%1.74B | -29.22%648.68M | 51.89%6.11B | 22.62%3.55B |
| Operating cost | 45.03%5.16B | 42.65%3.68B | 78.16%2.71B | 163.18%1.41B | -37.30%3.56B | -20.67%2.58B | -23.72%1.52B | -34.50%537M | 50.29%5.68B | 19.73%3.25B |
| Operating tax surcharges | -17.73%11.55M | -38.27%6.87M | -7.20%6.77M | 15.30%1.19M | -54.51%14.04M | -44.57%11.13M | -46.75%7.3M | -73.26%1.03M | 19.58%30.87M | 40.68%20.08M |
| Operating expense | -5.22%14.72M | -6.73%11.94M | 16.48%7.85M | 55.90%4.2M | -6.35%15.53M | 12.58%12.8M | 18.04%6.74M | 53.95%2.7M | -15.25%16.58M | -33.29%11.37M |
| Administration expense | 40.41%125.36M | -44.56%82.18M | -60.79%49.76M | -72.14%21.78M | -14.84%89.28M | 156.94%148.22M | 242.10%126.92M | 321.60%78.18M | 8.15%104.83M | 3.93%57.69M |
| Financial expense | 40.58%42.79M | 56.37%35.16M | 33.05%21.68M | 43.08%9.88M | -61.69%30.44M | -67.55%22.48M | -71.63%16.29M | -46.25%6.9M | 152.45%79.46M | 124.74%69.28M |
| -Interest expense (Financial expense) | 41.76%52.37M | 54.56%41.94M | 44.86%26.61M | 25.90%12.82M | -24.93%36.95M | -30.78%27.14M | -30.55%18.37M | -20.68%10.18M | 50.13%49.22M | 113.59%39.2M |
| -Interest Income (Financial expense) | 10.98%-14.8M | 18.26%-10.37M | 9.82%-7.89M | 11.89%-4.15M | -14.62%-16.62M | -33.87%-12.68M | -51.52%-8.75M | -106.29%-4.71M | -42.51%-14.5M | -34.22%-9.47M |
| Research and development | -10.58%154.34M | -6.70%128.14M | 54.69%98.6M | 150.72%57.33M | -13.91%172.61M | 1.46%137.34M | -30.28%63.74M | -61.64%22.87M | 183.12%200.5M | 134.26%135.37M |
| Credit Impairment Loss | -144.07%-1.28M | -12.46%-3.52M | 2.70%-4.58M | -265.77%-1.92M | -80.99%2.9M | -280.54%-3.13M | 53.35%-4.71M | -111.64%-526.11K | 384.49%15.25M | 119.18%1.73M |
| Asset Impairment Loss | 31.00%878.3K | -218.92%-756.65K | -478.13%-2.99M | -1,127.44%-2.96M | 181.70%670.48K | 143.07%636.25K | 94.96%-516.78K | 80.15%-241.44K | 87.03%-820.63K | -38.23%-1.48M |
| Other net revenue | 1,503.67%144.46M | 1,201.80%34.79M | 409.63%19.23M | -484.06%-5.79M | -42.73%9.01M | -295.02%-3.16M | 67.52%-6.21M | 60.55%-991.55K | 114.15%15.73M | 112.21%1.62M |
| Fair value change income | 35.98%1.57M | 107.88%1.91M | 161.20%1.42M | -175.13%-312.55K | -35.39%1.15M | -39.53%918.9K | -54.95%542.57K | 393.65%415.99K | 42.94%1.79M | 40.76%1.52M |
| Invest income | -222.98%-3.14M | 2.24%-2.1M | 43.90%-1.14M | -4.17%-1M | 183.06%2.55M | -2.38%-2.15M | -7.39%-2.03M | -1.35%-960K | -206.23%-3.07M | 55.88%-2.1M |
| -Including: Investment income associates | -324.95%-3.94M | ---- | ---- | ---- | 145.37%1.75M | ---- | ---- | ---- | 59.67%-3.86M | ---- |
| Asset deal income | --97.23M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other revenue | 2,737.63%49.2M | 6,875.83%39.25M | 5,282.25%26.52M | 27.85%409.13K | -33.05%1.73M | -70.99%562.72K | -74.12%492.72K | 700.00%320K | -82.61%2.59M | 276.62%1.94M |
| Operating profit | 9.94%-582.3M | -15.24%-535.66M | -17.98%-371.67M | -60.76%-207.68M | -1,347.83%-646.59M | -51.93%-464.81M | -64.63%-315.03M | -94.71%-129.19M | -119.22%-44.66M | -264.72%-305.93M |
| Add:Non operating Income | 83.51%45.67M | -54.63%40.87K | -67.37%26.86K | -97.83%1K | -1.04%24.89M | -84.60%90.08K | -47.85%82.31K | 394.88%46.14K | 11,932.69%25.15M | 414.39%585.11K |
| Less:Non operating expense | 5,681.23%95.12M | -56.53%728.21K | -99.62%1.64K | ---- | -93.42%1.65M | -92.50%1.68M | -97.91%435.87K | -99.95%3.5K | 20,630.20%25.02M | 702,720.85%22.33M |
| Total profit | -1.35%-631.76M | -15.00%-536.35M | -17.84%-371.65M | -60.81%-207.68M | -1,299.82%-623.34M | -42.33%-466.39M | -48.74%-315.38M | -76.69%-129.15M | -119.15%-44.53M | -276.32%-327.68M |
| Less:Income tax cost | 100.24%249.99K | 101.25%899.76K | -14.12%-56.13M | -52.76%-30.3M | -1,526.24%-102.33M | -42.58%-71.94M | -62.53%-49.18M | -132.84%-19.84M | -114.08%-6.29M | -173.82%-50.45M |
| Net profit | -21.30%-632.01M | -36.20%-537.25M | -18.53%-315.52M | -62.27%-177.38M | -1,262.55%-521.01M | -42.29%-394.46M | -46.45%-266.2M | -69.28%-109.31M | -120.36%-38.24M | -335.94%-277.22M |
| Net profit from continuing operation | -21.30%-632.01M | -36.20%-537.25M | -18.53%-315.52M | -62.27%-177.38M | -1,262.55%-521.01M | -42.29%-394.46M | -46.45%-266.2M | -69.28%-109.31M | -120.36%-38.24M | -335.94%-277.22M |
| Less:Minority Profit | --136.49K | --546.16 | ---24.5 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net profit of parent company owners | -21.33%-632.14M | -36.20%-537.25M | -18.53%-315.52M | -62.27%-177.38M | -1,262.55%-521.01M | -42.29%-394.46M | -46.45%-266.2M | -69.28%-109.31M | -120.36%-38.24M | -335.94%-277.22M |
| Earning per share | ||||||||||
| Basic earning per share | -29.55%-0.57 | -45.45%-0.48 | -27.27%-0.28 | -77.78%-0.16 | -1,366.67%-0.44 | -43.48%-0.33 | -46.67%-0.22 | -80.00%-0.09 | -118.75%-0.03 | -330.00%-0.23 |
| Diluted earning per share | -29.55%-0.57 | -45.45%-0.48 | -27.27%-0.28 | ---- | -1,366.67%-0.44 | -43.48%-0.33 | -46.67%-0.22 | ---- | -118.75%-0.03 | -330.00%-0.23 |
| Other composite income | 87.09%-136.92K | -131.30%-182.28K | -1.52%-126.48K | -18.61%-73.07K | -70.71%-1.06M | 231.28%582.41K | 71.93%-124.59K | -357.20%-61.6K | 96.22%-621.05K | 81.12%-443.63K |
| Other composite income of parent company owners | 87.09%-136.92K | -131.30%-182.28K | -1.52%-126.48K | -18.61%-73.07K | -70.71%-1.06M | 231.28%582.41K | 71.93%-124.59K | -357.20%-61.6K | 96.22%-621.05K | 81.12%-443.63K |
| Total composite income | -21.08%-632.14M | -36.45%-537.43M | -18.52%-315.65M | -62.25%-177.45M | -1,243.51%-522.07M | -41.85%-393.88M | -46.16%-266.32M | -69.34%-109.37M | -122.68%-38.86M | -341.14%-277.67M |
| Total composite income of parent company owners | -21.11%-632.28M | -36.45%-537.43M | -18.52%-315.65M | -62.25%-177.45M | -1,243.51%-522.07M | -41.85%-393.88M | -46.16%-266.32M | -69.34%-109.37M | ---38.86M | ---277.67M |
| Total composite income of minority owners | --136.49K | --546.16 | ---24.5 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs